Eplerenone

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1914 publications

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Journal: Retina (Philadelphia, Pa.)

Published: June 22, 2026

Which aldosterone antagonist? Choosing between sprionolactone and the novel drug finerenone

Which aldosterone antagonist? Choosing between sprionolactone and the novel drug finerenone

Journal: Nederlands tijdschrift voor geneeskunde

Published: June 15, 2026

Sex Differences in the Renal T Cell Profile in DOCA-Salt Hypertension are Independent of MR Activation and Increases in Blood Pressure.

Sex Differences in the Renal T Cell Profile in DOCA-Salt Hypertension are Independent of MR Activation and Increases in Blood Pressure.

Journal: American journal of physiology. Renal physiology

Published: June 08, 2026

NT-proBNP reference and cut-off values should be adjusted to patient's age in clinical practice - results of national representative survey POLSENIOR 2.

NT-proBNP reference and cut-off values should be adjusted to patient's age in clinical practice - results of national representative survey POLSENIOR 2.

Journal: Kardiologia polska

Published: May 15, 2026

Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials.

Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials.

Journal: Renal failure

Published: April 29, 2026

Can we differentiate between finerenone, eplerenone and spironolactone in HFmrEF/HFpEF through a Bayesian lens?

Can we differentiate between finerenone, eplerenone and spironolactone in HFmrEF/HFpEF through a Bayesian lens?

Journal: European journal of heart failure

Published: March 22, 2026

Real-World Benefit of Spironolactone and Eplerenone in HFpEF: Evidence From a Large-Scale Observational Study.

Real-World Benefit of Spironolactone and Eplerenone in HFpEF: Evidence From a Large-Scale Observational Study.

Journal: American journal of therapeutics

Published: March 17, 2026

Human 3D Cardiac Microtissue Model to Investigate Aldosterone-Induced Fibrosis and Electrical Dysfunction.

Human 3D Cardiac Microtissue Model to Investigate Aldosterone-Induced Fibrosis and Electrical Dysfunction.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: March 16, 2026

The Pharmacological Properties and Safety Profile of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.

The Pharmacological Properties and Safety Profile of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.

Journal: The Journal of the Association of Physicians of India

Published: March 12, 2026

Risk of Delaying or Omitting Mineralocorticoid Receptor Antagonists in Heart Failure.

Risk of Delaying or Omitting Mineralocorticoid Receptor Antagonists in Heart Failure.

Journal: The Journal of the Association of Physicians of India

Published: March 12, 2026

Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution.

Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution.

Journal: The Journal of the Association of Physicians of India

Published: March 12, 2026

Mineralocorticoid Receptor Antagonists: The Pillar Drug in Heart Failure.

Mineralocorticoid Receptor Antagonists: The Pillar Drug in Heart Failure.

Journal: The Journal of the Association of Physicians of India

Published: March 12, 2026

Showing 1-12 of 1,914

Last Updated: 06/30/2026